Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
The generation of anti-tumoral cells using dendritic cells from the peripheral blood of patients with malignant brain tumors
Autore:
Yoshida, S; Morii, K; Watanabe, M; Saito, T; Yamamoto, K; Tanaka, R;
Indirizzi:
Niigata Canc Ctr Hosp, Dept Neurosurg, Niigata 951, Japan Niigata Canc CtrHosp Niigata Japan 951 pt Neurosurg, Niigata 951, Japan Niigata Univ, Brain Res Inst, Dept Neurosurg, Niigata 95021, Japan NiigataUniv Niigata Japan 95021 t, Dept Neurosurg, Niigata 95021, Japan
Titolo Testata:
CANCER IMMUNOLOGY IMMUNOTHERAPY
fascicolo: 6, volume: 50, anno: 2001,
pagine: 321 - 327
SICI:
0340-7004(200108)50:6<321:TGOACU>2.0.ZU;2-U
Fonte:
ISI
Lingua:
ENG
Soggetto:
EPIDERMAL LANGERHANS CELLS; ANTITUMOR IMMUNITY; T-CELLS; MELANOMA PATIENTS; INDUCTION; GLIOMA; SYSTEM; VACCINATION; DEPENDENCE; SURVIVAL;
Keywords:
dendritic cells; malignant brain tumors; immunotherapy; glioma;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
37
Recensione:
Indirizzi per estratti:
Indirizzo: Yoshida, S Niigata Canc Ctr Hosp, Dept Neurosurg, Kawagishi Chou 2-15-3, Niigata 951,Japan Niigata Canc Ctr Hosp Kawagishi Chou 2-15-3 Niigata Japan951
Citazione:
S. Yoshida et al., "The generation of anti-tumoral cells using dendritic cells from the peripheral blood of patients with malignant brain tumors", CANCER IMMU, 50(6), 2001, pp. 321-327

Abstract

Dendritic cells (DCs) can be the principal initiators of antigen-specific immune responses. We analyzed the in vitro-responses against brain tumor cells using DCs from the peripheral blood of patients with brain tumors. Peripheral blood mononuclear cells (PBMC) were obtained from 19 patients with malignant brain tumors: 12 metastatic brain tumors of lung adenocarcinoma, 7high-grade astrocytomas. PBMC were cultured with 100 ng/ml of GM-CSF and 10 ng/ml of IL-4 for 5-7 days in order to produce mature DCs. The autologoustumor lysate (5 mg/ml, containing 1 x 10(6) cells) was then added to the cultured DCs. Using the DCs generated by these treatments, we assessed the changes that occurred in their immune responses against brain tumor via Cr-51-release and lymphocyte proliferation assays. We found that the matured DCs displayed the typical surface phenotype of CD3(+) CD45(+) CD80(+) and CD86(+). After the pulsation treatment with tumor lysate, DCs were found to have strong cytotoxic T lymphocyte activity, showing 42.5 +/- 12.7% killing of autologous tumor cells. We also found an enhancement of allogeneic T cellproliferation after pulsing the DC with tumor lysate. These data support the efficacy of DC-based immunotherapy for patients with malignant brain tumors.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 30/03/20 alle ore 08:44:14